Unknown

Dataset Information

0

Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report.


ABSTRACT: Tenofovir alafenamide (TAF) is one of the most potent first-line nucleot(s)ide analogs for treating chronic hepatitis B virus (HBV) infections. To date, no cases of TAF drug resistance and/or suboptimal response have been reported. To our knowledge, this is the first report of two adult male patients presenting a suboptimal response response to TAF monotherapy. Our study indicates long-term observations and extensive data are needed to further evaluate the efficacy and safety of TAF, and highlights the need for the development of robust novel direct-acting antivirals and immune therapies for HBV.

SUBMITTER: Chen R 

PROVIDER: S-EPMC8295557 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC10548823 | biostudies-literature
| S-EPMC10776286 | biostudies-literature
| S-EPMC7364362 | biostudies-literature
| S-EPMC8686386 | biostudies-literature
| S-EPMC3563589 | biostudies-literature
| S-EPMC7533205 | biostudies-literature
| S-EPMC8775237 | biostudies-literature
| S-EPMC3999385 | biostudies-literature
| S-EPMC6232567 | biostudies-literature
| S-EPMC2716864 | biostudies-other